ClinicalTrials.gg
CompletedNCT00071812Updated Aug 14, 2013Results posted

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

A Phase 2 interventional study of Placebo and Belimumab 1 mg/kg in Arthritis, Rheumatoid, sponsored by Human Genome Sciences Inc.. Completed at 63 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-14.

Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · GlaxoSmithKline.

Enrollment
6th of 40
283 · median 52
Started
2003
the only one that year
Phase 2
17 of 44
none open now
Registered
2nd of 44
by date

Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, this one is the 6th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2003, is one of 17 in phase 2, and was the 2nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with rheumatoid arthritis (RA).

Read the detailed description

The purpose of this study is to evaluate the safety and efficacy of three different doses of belimumab (1 mg/kg, 4 mg/kg, and 10 mg/kg), administered in addition to standard therapy, compared to placebo plus standard therapy in patients with RA. All patients were to be dosed on Days 0, 14, and 28, then every 28 days for the remainder of 24 weeks. Patients completing the 24-week period could enter a 24-week open-label extension; belimumab patients received the same dose or were switched to 10 mg/kg at the investigator's discretion and former placebo patients received belimumab 10 mg/kg.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • RA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion Criteria:

  • Diagnosis of RA for at least 1 year
  • Failed at least 1 disease modifying anti-rheumatic drug (DMARD) due to toxicity or lack of efficacy. These drugs must include 1 or more of the following: methotrexate, parenteral gold, sulfasalazine, leflunomide, and tumor necrosis factor-alpha (TNFα) inhibitors (infliximab, etanercept or adalimumab)
  • Active RA disease of at least moderate disease activity
  • Be on a stable RA treatment regimen for at least the past 60 days (for DMARDS); if on non-steroidal anti-inflammatory drugs (NSAIDs) or these must be at a stable dose for the last 30 days

Primary Exclusion Criteria:

  • Received a non-FDA approved agent within the last 28 days
  • Currently receiving or received within the last 60 days the following: TNFα-inhibitors (infliximab, etanercept, adalimumab) or interleukin-1 receptor antagonist (anakinra)
  • Currently receiving or received within the last 6 months the following: anti-CD20 antibody (rituximab) or cyclophosphamide
  • Steroid injection into any joint within the last 30 days
  • History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency
  • History of chronic infection that has been active within last 6 months, or herpes zoster within last 90 days, or any infection requiring hospitalization or intravenous medication within last 60 days
  • (HIV), Hepatitis-B, Hepatitis-C
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
283 participants (actual)

Study arms

  • Placebo comparator
    Placebo plus SOC

    Drug: Placebo

  • Experimental
    Belimumab 1 mg/kg plus SOC

    Drug: Belimumab 1 mg/kg

  • Experimental
    Belimumab 4 mg/kg plus SOC

    Drug: Belimumab 4 mg/kg

  • Experimental
    Belimumab 10 mg/kg plus SOC

    Drug: Belimumab 10 mg/kg

Interventions

  • DrugPlacebo

    Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.

  • DrugBelimumab 1 mg/kg

    Drug page: Belimumab

    Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.

    Also known as: LymphoStat-B®, BENLYSTA®

  • DrugBelimumab 4 mg/kg

    Drug page: Belimumab

    Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.

    Also known as: LymphoStat-B®, BENLYSTA®

  • DrugBelimumab 10 mg/kg

    Drug page: Belimumab

    Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.

    Also known as: LymphoStat-B®, BENLYSTA®

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)

    An ACR20 response is defined as having at least a 20% improvement in tender and swollen joints as well as a 20% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).

    Time frame: Baseline, 24 weeks

Secondary outcomes

  1. Percentage of Patients With an ACR50 Response at Week 24, Based on ESR

    An ACR50 response is defined as having at least a 50% improvement in tender and swollen joints as well as a 50% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).

    Time frame: Baseline, 24 weeks

  2. Percentage of Patients With an ACR70 Response at Week 24, Based on ESR

    An ACR70 response is defined as having at least a 70% improvement in tender and swollen joints as well as a 70% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).

    Time frame: Baseline, 24 weeks

  3. Time to First ACR20 Response, Based on ESR

    The time to first ACR20 response (based on ESR) is defined as the time from the first dose to the first visit at which a patient first exhibited an ACR20 response, which may or may not have been sustained through Week 24.

    Time frame: 0 to 24 weeks

  4. Time to First ACR50 Response, Based on ESR

    Measure not posted because time to ACR50 response was unable to be determined due to the small number of patients achieving an ACR50 response in the study.

    Time frame: 0 to 24 weeks

  5. Time to First ACR70 Response, Based on ESR

    Measure not posted because time to ACR70 response was unable to be determined due to the small number of patients achieving an ACR70 response in the study.

    Time frame: 0 to 24 weeks

  6. Mean Change in Disease Activity Score 28 (DAS28) at Week 24

    DAS is a composite index of a patient's level of RA disease activity. DAS28 is an abbreviated version of DAS, using a subset of 28 joints in the assessment, calculated based on 4 variables: 1) number of tender joints out of a total of 28 joints, 2) number of swollen joints out of a total of 28 joints, 3) ESR, 4) patient's global assessment of disease activity based on a 100-mm visual analog scale. The calculation provides a number on a scale from 0 to 10 (\>5.1=active disease; \<3.2=well controlled disease; \<2.6=remission). Change from baseline \>1.2 = good response and ≤0.6 = non-response.

    Time frame: Baseline, 24 weeks

  7. Time to First DAS28 Response

    DAS28 response is defined as the time from the first dose to the first time at which a patient exhibited a "good" or a "moderate" improvement in RA disease activity, based on DAS28 improvements compared to baseline. Good response was defined as \>1.2 change from baseline and DAS28 score ≤ 3.2. No response was defined as ≤ 0.6 change from baseline in DAS28 score or change between ≤ 1.2 and \> 0.6 with a DAS28 score of \> 5.1.

    Time frame: 0 to 24 weeks

  8. Mean Change in Modified Total Sharp Score at Week 24

    The modified total Sharp score method was used to evaluate radiographs of hands/wrists for erosions (ERO) and joint space narrowing (JSN). The total modified Sharp score ranges from 0 (no radiographic damage) to 200 (worst possible radiographic damage) and is the sum of the normalized ERO score (range 0-100) and the normalized JSN score (range 0-100). Higher scores indicated more damage.

    Time frame: Baseline, 24 weeks

Other outcomes

  1. Adverse Events (AE) Overview

    Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).

    Time frame: Up to 56 weeks

07

Results

Posted Jun 25, 2012

Participant flow

24-Week Double-Blind Period
Participant flow — 24-Week Double-Blind Period
MilestonePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Started69727171
Completed59666360
Not completed106811
Withdrew: Adverse event2344
Withdrew: Lack of efficacy3121
Withdrew: Lost to follow-up0110
Withdrew: Withdrawal by subject5115
Withdrew: Protocol violation0001
24-Week Open-Label Extension Period
Participant flow — 24-Week Open-Label Extension Period
MilestonePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Started0118218
Completed0117178
Not completed00140
Withdrew: Adverse event0007
Withdrew: Lack of efficacy00017
Withdrew: Lost to follow-up0002
Withdrew: Withdrawal by subject00012
Withdrew: Lack of compliance0012

Outcome measures

PrimaryPercentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)

An ACR20 response is defined as having at least a 20% improvement in tender and swollen joints as well as a 20% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).

Time frame:
Baseline, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)
percentage of participantsPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)15.934.725.428.2
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.0097 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 18.8 · 95% CI 4.8 to 32.8
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.1677 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 9.4 · 95% CI -3.9 to 22.7
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.0796 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 12.2 · 95% CI -1.3 to 25.8
SecondaryPercentage of Patients With an ACR50 Response at Week 24, Based on ESR

An ACR50 response is defined as having at least a 50% improvement in tender and swollen joints as well as a 50% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).

Time frame:
Baseline, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Patients With an ACR50 Response at Week 24, Based on ESR
percentage of participantsPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Percentage of Patients With an ACR50 Response at Week 24, Based on ESR4.39.78.514.1
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.2074 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 5.4 · 95% CI -3.0 to 13.7
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.3177 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 4.1 · 95% CI -4.0 to 12.2
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.0418 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 9.7 · 95% CI 0.3 to 19.2
SecondaryPercentage of Patients With an ACR70 Response at Week 24, Based on ESR

An ACR70 response is defined as having at least a 70% improvement in tender and swollen joints as well as a 70% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).

Time frame:
Baseline, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Patients With an ACR70 Response at Week 24, Based on ESR
percentage of participantsPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Percentage of Patients With an ACR70 Response at Week 24, Based on ESR2.95.61.42.8
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.4299 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 2.7 · 95% CI -4.0 to 9.3
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.5393 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: -1.5 · 95% CI -6.3 to 3.3
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.9769 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: -0.1 · 95% CI -5.6 to 5.4
SecondaryTime to First ACR20 Response, Based on ESR

The time to first ACR20 response (based on ESR) is defined as the time from the first dose to the first visit at which a patient first exhibited an ACR20 response, which may or may not have been sustained through Week 24.

Time frame:
0 to 24 weeks
Reported as:
Median · days
Time to First ACR20 Response, Based on ESR
daysPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Time to First ACR20 Response, Based on ESR112 (84 to NA)109 (60 to 168)112 (49 to NA)111 (57 to NA)
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Log Rank · p = 0.1752 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Log Rank · p = 0.3440 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Log Rank · p = 0.4308 (P-value was not adjusted for multiple testing.)
SecondaryTime to First ACR50 Response, Based on ESR

Measure not posted because time to ACR50 response was unable to be determined due to the small number of patients achieving an ACR50 response in the study.

Time frame:
0 to 24 weeks

Results for this outcome have not been posted.

SecondaryTime to First ACR70 Response, Based on ESR

Measure not posted because time to ACR70 response was unable to be determined due to the small number of patients achieving an ACR70 response in the study.

Time frame:
0 to 24 weeks

Results for this outcome have not been posted.

SecondaryMean Change in Disease Activity Score 28 (DAS28) at Week 24

DAS is a composite index of a patient's level of RA disease activity. DAS28 is an abbreviated version of DAS, using a subset of 28 joints in the assessment, calculated based on 4 variables: 1) number of tender joints out of a total of 28 joints, 2) number of swollen joints out of a total of 28 joints, 3) ESR, 4) patient's global assessment of disease activity based on a 100-mm visual analog scale. The calculation provides a number on a scale from 0 to 10 (\>5.1=active disease; \<3.2=well controlled disease; \<2.6=remission). Change from baseline \>1.2 = good response and ≤0.6 = non-response.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · scores on a scale
Mean Change in Disease Activity Score 28 (DAS28) at Week 24
scores on a scalePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Mean Change in Disease Activity Score 28 (DAS28) at Week 24-0.9 ± 0.15-1.3 ± 0.18-0.9 ± 0.14-1.5 ± 0.15
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · t-test, 2 sided · p = 0.0958 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · t-test, 2 sided · p = 0.7864 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · t-test, 2 sided · p = 0.0051 (P-value was not adjusted for multiple testing.)
SecondaryTime to First DAS28 Response

DAS28 response is defined as the time from the first dose to the first time at which a patient exhibited a "good" or a "moderate" improvement in RA disease activity, based on DAS28 improvements compared to baseline. Good response was defined as \>1.2 change from baseline and DAS28 score ≤ 3.2. No response was defined as ≤ 0.6 change from baseline in DAS28 score or change between ≤ 1.2 and \> 0.6 with a DAS28 score of \> 5.1.

Time frame:
0 to 24 weeks
Reported as:
Median · days
Time to First DAS28 Response
daysPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Time to First DAS28 Response111 (56 to 168)82 (51 to 114)84 (33 to 168)57 (30 to 111)
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Log Rank · p = 0.0960 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Log Rank · p = 0.2859 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Log Rank · p = 0.0109 (P-value was not adjusted for multiple testing.)
SecondaryMean Change in Modified Total Sharp Score at Week 24

The modified total Sharp score method was used to evaluate radiographs of hands/wrists for erosions (ERO) and joint space narrowing (JSN). The total modified Sharp score ranges from 0 (no radiographic damage) to 200 (worst possible radiographic damage) and is the sum of the normalized ERO score (range 0-100) and the normalized JSN score (range 0-100). Higher scores indicated more damage.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · scores on a scale
Mean Change in Modified Total Sharp Score at Week 24
scores on a scalePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Mean Change in Modified Total Sharp Score at Week 240.7 ± 0.20.3 ± 0.20.3 ± 0.20.6 ± 0.2
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · t-test, 2 sided · p = 0.1940 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · t-test, 2 sided · p = 0.2561 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · t-test, 2 sided · p = 0.8707 (P-value was not adjusted for multiple testing.)
Other pre-specifiedAdverse Events (AE) Overview

Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).

Time frame:
Up to 56 weeks
Reported as:
Number · percentage of participants
Adverse Events (AE) Overview
percentage of participantsPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCOpen-label Extension Period: All Active
Percent of patients with at least 1 AE89.984.790.193.091.6
Percent of patients with at least 1 SAE7.26.97.08.511.0
Percent of patients with an AE resulting in death1.5001.40

Adverse events

Collected over Up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Plus SOC—5/69 (7.2%)50/69 (72.5%)
Belimumab 1 mg/kg Plus SOC—5/72 (6.9%)47/72 (65.3%)
Belimumab 4 mg/kg Plus SOC—5/71 (7%)48/71 (67.6%)
Belimumab 10 mg/kg Plus SOC—6/71 (8.5%)54/71 (76.1%)
Open-label Extension Period: All Active—26/237 (11%)165/237 (69.6%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCOpen-label Extension Period: All Active
Cardiac arrestCardiac disorders1/690/720/710/710/237
Myocardial infarctionCardiac disorders1/690/721/710/710/237
Non-cardiac chest painGeneral disorders1/690/721/710/710/237
CholecystitisHepatobiliary disorders1/690/720/710/710/237
CholelithiasisHepatobiliary disorders1/690/720/711/710/237
Viral infectionInfections and infestations1/690/720/710/710/237
ArthropathyMusculoskeletal and connective tissue disorders1/690/720/710/710/237
Ovarian cystReproductive system and breast disorders1/690/720/710/710/237
AnaemiaBlood and lymphatic system disorders0/690/720/711/711/237
Acute coronary syndromeCardiac disorders0/690/721/710/710/237
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCOpen-label Extension Period: All Active
ArthralgiaMusculoskeletal and connective tissue disorders16/6921/7215/7124/7175/237
Upper respiratory tract infectionInfections and infestations9/696/729/7110/7138/237
Joint swellingMusculoskeletal and connective tissue disorders3/694/726/7111/7121/237
Oedema peripheralGeneral disorders4/693/729/713/7125/237
DiarrhoeaGastrointestinal disorders6/696/722/718/7115/237
Urinary tract infectionInfections and infestations6/698/728/714/7117/237
HeadacheNervous system disorders4/697/725/718/7112/237
CoughRespiratory, thoracic and mediastinal disorders2/691/723/718/7112/237
FatigueGeneral disorders4/695/726/717/7118/237
SinusitisInfections and infestations2/693/727/713/7113/237

Baseline characteristics

Age Continuous
Age Continuous(years)Placebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCTotal
Mean50.7 ± 8.850.6 ± 8.350.7 ± 10.249.5 ± 9.350.4 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCTotal
Female56566054226
Male1316111757
Region of Enrollment
Region of Enrollment(participants)Placebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCTotal
United States55615959234
Poland1411121249
08

Study locations

63 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-0006, United States
  • Arizona Arthritis Research
    Paradise Valley, Arizona 85253, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Scripps Clinic
    LaJolla, California 92037, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Wallace Rheumatic Disease Center
    Los Angeles, California 90048, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • Boling Clinical Trials
    Rancho Cucamonga, California 91730, United States
  • UCDMC
    Sacramento, California 95817-1418, United States
  • Arthritis Care Center, Inc.
    San Jose, California 95126-1650, United States
  • Arthritis Associates & Osteoporosis Center Of Colorado Springs
    Colorado Springs, Colorado 80910, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Arthritis and Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Tampa Medical Group, P.A.
    Tampa, Florida 33614, United States
  • Radiant Research Boise
    Boise, Idaho 83704, United States
  • Institute of Arthritis and Research
    Idaho Falls, Idaho 83404, United States
  • Northwestern University Medical School
    Chicago, Illinois 60611, United States
  • Rheumatology Associates
    Chicago, Illinois 60612, United States
  • Rockford Clinic
    Rockford, Illinois 61103, United States
  • Medical Specialists
    Munster, Indiana 46321, United States
  • Kentuckiana Center for Better Bone and Joint Health
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    Baton Rouge, Louisiana 70809, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • The Osteoporosis and Arthritis Clinical Trial Center
    Cumberland, Maryland 21502, United States
  • Center for Rhematology and Bone Research
    Wheaton, Maryland 20902, United States
  • Tufts - New England Medical Center
    Boston, Massachusetts 02111, United States
  • The University of Michigan Health System
    Ann Arbor, Michigan 48109-0358, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University in St. Louis
    St. Louis, Missouri 63110, United States
  • Arthritis Center of Nebraska
    Lincoln, Nebraska 68506, United States
  • Arthritis and Osteoporosis Center
    Concord, New Hampshire 03301, United States
  • Strafford Medical Associates, P.A.
    Dover, New Hampshire 03820, United States
  • The Center For Rheumatology
    Albany, New York 12206, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • SUNY-Downstate Medical Center
    Brooklyn, New York 11203, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-7280, United States
  • Arthritis Clinic and Carolina Bone and Joint
    Charlotte, North Carolina 28210, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Stat Research, Inc.
    Dayton, Ohio 45402, United States
  • McBride Clinic
    Oklahoma City, Oklahoma 73101, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Center For Arthritis Therapy & Research
    Tulsa, Oklahoma 74114, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh School of Medicine & ASPH
    Pittsburgh, Pennsylvania 15261, United States
  • Rheumatic Disease Associates
    Willow Grove, Pennsylvania 19090, United States
  • Arthritis Centers of Texas
    Dallas, Texas 75246, United States
  • Research Associates of North Texas
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390-8884, United States
  • Houston Institute for Clinical Research
    Houston, Texas 77074, United States
  • Texas Research Center
    Sugar Land, Texas 77479, United States
  • Arthritis and Rheumatic Diseases Clinic
    Weber, Utah 84403, United States
  • Arthritis Clinic of Northern Virginia, P.C.
    Arlington, Virginia 22205, United States
  • Edmonds Rheumatology Associates
    Edmonds, Washington 98026-8047, United States
  • Evergreen Clinical Reserach
    Edmonds, Washington 98026-8047, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • Rheumatology Northwest Clinical Trials
    Yakima, Washington 98902, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Gundersen Clinic, Ltd.
    La Crosse, Wisconsin 54610, United States
  • The Medical College of Wisconsin , Inc
    Milwaukee, Wisconsin 53226, United States
  • Marshfield Medical Research Foundation
    Wausau, Wisconsin 54401, United States
09

References and documents

Publications

  • Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May;40(5):579-89. doi: 10.3899/jrheum.120886. Epub 2013 Apr 1. PubMed 23547209 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Jan 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 7 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2003
First posted
Nov 5, 2003
Start
Dec 2003
Primary completionActual
Jan 2005
CompletionActual
Dec 2005
Results first posted
Jun 25, 2012
Last update
Aug 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00071812
Responsible party
Sponsor
First posted
Nov 5, 2003
Start date
Dec 2003
Primary completion
Jan 2005
Completion
Dec 2005
Results posted
Jun 25, 2012
Last update
Aug 14, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion